Immuneering Q3 Net Loss Widens 62% to $24.19 Million

By Public Technologies
  • Immuneering’s third-quarter 2026 net loss widened 62% year over year to $24.19 million.
  • Research and development expenses jumped 91% to $20.72 million, primarily due to higher clinical costs and increased personnel.
  • Cash, cash equivalents and marketable securities totaled $166.1 million at September 30, with operations funded into the fourth quarter of 2028.
  • Phase 2 pancreatic cancer follow-up was extended because patients lived longer than projected; updated data are expected in first-half 2027.
  • Ahead-of-schedule MAPKeeper 301 enrollment supports expansion to approximately 570 patients, potentially accelerating the currently expected mid-2028 topline readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291605PRIMZONEFULLFEED9856352) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.